PREMIA and AmoyDx announce partnership to establish Asia Cancer Clinical Genomic Network
Singapore, June 25 -- Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics and PREMIA Holdings (HK) Ltd.
Under the agreement, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292, Loxo Oncology's RET (rearranged during transfection) kinase inhibitor which leverages AmoyDx's proprietary multi-gene polymerase chain reaction (PCR) and next generation sequencing (NGS) panels to identify patients with this rare genetic alteration.
Wenn Sun, founder and president of PREMIA and Li-Mou Zheng, founder and chief executive officer of AmoyDx said, "We are extremely pleased to ann...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.